Coriolus versicolor Mushroom Extract Boosts Survival in Colorectal Cancer Patients

Coriolus versicolor Mushroom Extract Boosts Survival in Colorectal Cancer Patients

Coriolus versicolor, also known as turkey tail mushroom, has long been prized in traditional Asian medicine for its immune-boosting properties. One of its key bioactive compounds, polysaccharide-K (PSK), is a protein-bound polysaccharide that modulates immune function and enhances the body’s defense against cancer. In Japan, PSK has been approved as an adjunct treatment for several cancers, including colorectal cancer, and is often prescribed alongside chemotherapy.

A landmark Japanese study by Sakai and colleagues, published in Cancer Biotherapy & Radiopharmaceuticals (2008), evaluated the long-term effects of adding PSK to standard chemotherapy with oral fluoropyrimidines in patients who had undergone curative resection for colorectal cancer. Participants received either chemotherapy alone or chemotherapy plus PSK for 24 months following surgery.

The results were striking. After 10 years, patients in the PSK group had a significantly higher overall survival rate—81.9% compared to 50.6% in the control group. The benefits were particularly evident in those with advanced disease or high-risk pathological features, where survival reached 80.6% with PSK versus just 25.9% without it. Statistical analysis confirmed PSK as an independent factor improving prognosis.

These findings highlight the powerful immunomodulatory effects of Coriolus versicolor extract when used alongside conventional therapy. By enhancing immune surveillance and possibly reducing tumor recurrence, PSK offers an evidence-based example of how medicinal mushrooms can complement modern oncology.

Reference:

Sakai T, Yamashita Y, Maekawa T, Takada K, Kodama M, Hata T, et al. Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer. Cancer Biother Radiopharm. 2008;23(4):507-513.